Sales increased, but the high production costs in one of its business segments adversely affected earnings for Eckert & Ziegler in 2012.
Consolidated sales increased 3% to 120 million euros in 2012, compared with 116.2 million euros in 2011.
Sales in the company's largest business segment, Isotope Products, grew by 3% to 56.1 million euros in 2012, while its Radiation Therapy unit achieved sales growth of 4% to 31.8 million euros last year.
The firm's earnings before interest, taxes, depreciation, and amortization (EBITDA) decreased to 27.5 million euros in 2012, compared with 30.4 million euros in 2011. Eckert & Ziegler blamed "disproportionately high costs" in production and administrative expenses costs, as well as one-time expenditures for an abandoned acquisition project as key reasons for the decline in earnings last year.
Thanks to lowered taxes, however, income after taxes and minority interest was $10.3 million euros, compared with 10.4 million euros in 2011.
For the next two years, the company anticipates sales of approximately 125 million euros in 2013 and at least 130 million euros in 2014.
